Abstract

The development of bacteria has been one of the most significant advances in medical science. The need for the development of novel antibacterial is clear, but the development of new antibacterial classes is more important. In this study, the new ruthenium complex bearing the NN chelating ligand 3,3’-dicarboxy-2,2’-bipyridine (3,3’-dcbpy) and the dimethylsulphoxide (DMSO) ligand, [Ru(3,3’-dcbpy) (DMSO)2Cl2], was synthesized and characterized using FT-IR, 1H- and 13C-NMR spectroscopy, elemental analysis, and UV-Vis spectrometry. In addition, the Ru-complex was examined for its activity as an antibacterial against gram-positive and gramnegative strains. Minimum Inhibitory Concentrations (MICs) and Minimum Bactericidal Concentrations (MBCs) of the compound were assessed using sterile 96-well plates, in accordance with the Clinical and Laboratory Standards Institute. The results show that the compound shows a MIC value of 35 µg mL−1 against Staphylococcus aureus and 65 µg mL−1 against Escherichia coli with the bacteria’s mode of action. In conclusion, Ru(3,3’-dcbpy) (DMSO)2Cl2 complex can be candidate as antibacterial agent against both gram-positive and gram-negative bacteria.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call